GD2-CAR T-cell Therapy is Safe in H3K27M⁺ Diffuse Midline Glioma

Main Finding: A phase I clinical trial demonstrates the safety of GD2-targeted CAR T-cell therapy in H3K27M⁺ diffuse midline glioma.
Concept: H3K27M⁺ diffuse midline gliomas express high levels of GD2, which enable CAR-mediated tumor regression.
Impact: This supports the efficacy of CAR T-cell therapy in lethal solid tumors and warrants further clinical investigation.